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Overview 
Background 
Oral hairy leukoplakia (OHL) is a disease of the mucosa first described in 1984. This pathology is 
associated with Epstein-Barr virus (EBV) and occurs mostly in people with HIV infection, both 
immunocompromised and immunocompetent, and can affect patients who are HIV negative.{ref1}{ref2} 
The first case in an HIV-negative patient was reported in 1999 in a 56-year-old patient with acute 
lymphocytic leukemia. Later, many cases were reported in heart, kidney, and bone marrow transplant 
recipients and patients with hematological malignancies.{ref3}{ref4} 
Pathophysiology 
The Epstein-Barr virus (EBV), a ubiquitous herpesvirus estimated to infect 90% of the world's population, 
is linked to a growing number of diseases, especially in immunocompromised hosts. Like all 
herpesviruses, EBV establishes a life-long, persistent infection of its host. The pathogenesis of hairy 
leukoplakia is clearly complex, potentially requiring a convergence of factors including EBV co-infection, 
productive EBV replication, EBV genetic evolution, expression of specific EBV "latent" genes, and 
immune escape. All of these factors are likely facilitated by local and systemic host 
immunodeficiency.{ref5} 
EBV initially infects basal epithelial cells in the pharynx, where it enters a replicative state leading to the 
release of infectious virus into the saliva throughout the life of the infected person. In the pharynx, the 
virus also enters B cells, where it persists indefinitely in a latent state. Cytotoxic T lymphocytes cannot 
eliminate EBV from the body, but they are essential in maintaining the latent state of the infection. In 
states of immune dysfunction in which the number of EBV-specific cytotoxic T lymphocytes is decreased, 
there is an increase in the number of circulating EBV-infected B cells. 
In addition, a marked decrease or an absence of Langerhans cells occurs in hairy leukoplakia biopsy 
tissues.{ref6}{ref7} Langerhans cells are the antigen-presenting immune cells that are required for an 
immune system response to the viral infection and their deficiency may permit EBV to persistently 
replicate and escape immune recognition. 
Epidemiology 
Frequency 
United States  
Hairy leukoplakia is one of the most common virally induced, oral diseases of HIV-infected individuals, 
with a point prevalence as high as 25-53%.{ref8} The 6-year incidence of oral hairy leukoplakia (OHL) in 
this patient population was reported to be around 32%. A significant trend to a lower prevalence of oral 
hairy leukoplakia was observed in the group of patients who were already taking antiretroviral therapy, 
non–highly active antiretroviral therapy (HAART) and HAART (P <.001 and P = .004, respectively).{ref9} 
Fewer cases of oral hairy leukoplakia were reported in non-HIV–infected patients. This is probably due to 
underdiagnosis and underreporting of this disease in patients with hematological malignancies or solid 
organ transplantation. Some studies showed the prevalence of oral hairy leukoplakia in renal transplant 
recipients to be more than 11%.{ref10} 
International  
The incidence of oral hairy leukoplakia is similar to that in the United States and thereby reflects the 
prevalence of HIV. In populations where the prevalence of HIV is low, oral mucosal lesions alone are poor 
prognostic predictors of HIV infection.{ref11} 
A cross-sectional study from Brazil reported on data collected from clinical examinations, interviews, and 
medical records for adult patients treated an HIV/AIDS clinic at the University Hospital of the Federal 
University in Rio Grande. Three hundred persons were observed (April 2006 to January 2007). Of these 
patients, 51% were male and the mean age was 40 years. Thirty-nine percent presented with oral lesions. 
The most common was candidiasis (59.1%), followed by hairy leukoplakia (19.5%).{ref12} 
A study from Saudi Arabia reported that compared with age and sex-matched healthy control subjects (N 
= 52), 8.6% of stable renal transplantation patients (N = 58) had oral leukoplakia. Other oral lesions 
reported were gingival hyperplasia (74.1%) and erythematous candidiasis (15.5%).{ref13} However, a 
study from Spain reported only one case of hairy leukoplakia in 500 renal transplant recipients 
studied.{ref14} 
Race 
No racial predilection has been established for oral hairy leukoplakia. 
Sex 
Oral hairy leukoplakia is most commonly observed in homosexual men who are HIV positive, especially in 
those who smoke. 
Age 
No age predilection has been established for oral hairy leukoplakia. 
Prognosis 
The majority of patients with oral hairy leukoplakia (OHL) tend to have significant immunosuppression at 
the time of diagnosis. Oral hairy leukoplakia occurs relatively soon after HIV seroconversion, typically 
before AIDS. Median CD4 count when oral hairy leukoplakia is first detected is 235-468/µL. Another study 
showed oral hairy leukoplakia occurred mostly in patients with CD4 counts of 200-500/µL.{ref15} 
In patients with HIV, the median CD4 count when oral hairy leukoplakia is first detected is 468/µL. If these 
patients do not have AIDS-defining disease at the time oral hairy leukoplakia is diagnosed, the probability 
of developing AIDS if not receiving highly active antiretroviral therapy (HAART) is 48% by 16 months and 
83% at 31 months. In addition, studies have shown that patients with AIDS with oral hairy leukoplakia 
have a shorter lifespan than those who do not present this lesion. Furthermore, if these patients are 
concomitantly co-infected with hepatitis B virus, the risk of early progression to AIDS increases 4-fold. 
Further studies in HIV-seropositive patients show that the median survival after the diagnosis of oral hairy 
leukoplakia is around 20 months. In patients with CD4 count greater than or equal to 300/μL, oral hairy 
leukoplakia is associated with median survival time of 25 months, compared with 52 months in patients 
with normal counts.{ref16} 
Presentation 
History 
Patients with oral hairy leukoplakia (OHL) may report a nonpainful white plaque along the lateral tongue 
borders. The appearance may change daily. The natural history of hairy leukoplakia is variable. Lesions 
may frequently appear and disappear spontaneously. Hairy leukoplakia is often asymptomatic, and many 
patients are unaware of its presence. Some patients with hairy leukoplakia do experience symptoms 
including mild pain, dysesthesia, alteration of taste, and the psychological impact of its unsightly cosmetic 
appearance. 
Physical Examination 
Unilateral or bilateral nonpainful white lesions can be seen on the margins, dorsal or ventral surfaces of 
the tongue, or on buccal mucosa, as shown in the image below. Oral hairy leukoplakia (OHL) lesions may 
vary in appearance from smooth, flat, small lesions to irregular "hairy" or "feathery" lesions with prominent 
folds or projections. 
 
Lateral tongue in oral hairy leukoplakia. 
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Lesions may be either continuous or discontinuous along both tongue borders, and they are often not 
bilaterally symmetric. Lesions are adherent, and only the most superficial layers can be removed by 
scraping. There is no associated erythema or edema of the surrounding tissue. Hairy leukoplakia may 
also involve dorsal and ventral tongue surfaces, the buccal mucosa, or the gingiva. On the ventral tongue, 
buccal mucosa, or gingiva, the lesion may be flat and smooth, lacking the characteristic "hairy" 
appearance.{ref2} 
See the image below. 
 Oral leukoplakia. 
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Causes 
Oral hairy leukoplakia (OHL) has been associated with HIV infection and/or immunosuppression.{ref17} 
The risk of developing oral hairy leukoplakia doubles with each 300-unit decrease in CD4 count. A high 
viral load was strongly associated to the oral lesions occurrence independently of CD4+ cell count.{ref8} 
More recently, it has been described in patients with other forms of severe immunodeficiency including 
those associated with chemotherapy, organ transplant, and leukemia. Rarely, it may occur in patients 
who are immunocompetent. 
Oral hairy leukoplakia also has been described in association with Behçet syndrome and ulcerative colitis. 
Smoking more than a pack of cigarettes a day is positively correlated with the development of oral hairy 
leukoplakia in HIV-positive men. 
No increase in oral hairy leukoplakia was observed when controlled for number of oral sex partners. 
Complications 
The complication associated with oral hairy leukoplakia (OHL) is an occasional candidal superinfection, 
which often results in an uncomfortable glossopyrosis (burning tongue). 
Altered taste sensation is a rare complication. 
The presence of oral lesions has a significant impact on health-related quality of life, because oral health 
is associated with physical and mental health.{ref18} 
DDx 
Diagnostic Considerations 
Also consider the following: 
 Geographic tongue 
 Frictional keratosis 
 Squamous cell carcinoma 
 Lichen planus 
 Tobacco-associated leukoplakia 
 Pseudo–hairy leukoplakia 
 Human papillomavirus (HPV)–induced neoplasia 
 Syphilitic mucous patch 
 Idiopathic leukoplakia 
 White sponge nevus 
 Hyperplastic candidiasis  
White sponge nevus, candidiasis, or thrush typically occurs as a flat lesion, removable by scraping, which reveals an 
erythematous base. However, hyperplastic candidiasis lesions are adherent and do not wipe off, making this disease 
especially difficult to distinguish from oral hairy leukoplakia (OHL). Resolution of the lesion with antifungal 
therapy suggests candidiasis over hairy leukoplakia. However, hairy leukoplakia lesions are commonly also infected 
with Candida, further confusing the clinical diagnosis. See the images below. 
 
White sponge nevus. 
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Hyperplastic candidiasis. 
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Frictional keratosis typically occurs on the lateral borders of the tongue as a consequence of tongue biting by the 
molar teeth or some other abrasive irritant (eg, from rubbing upon poorly fitting dental work), as shown in the image 
below. This lesion should quickly resolve after removal of the provoking stimulus. 
 Morsicatio linguarum, or tongue biting. 
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Tobacco-induced leukoplakia occurs in smokers and individuals who chew tobacco. These lesions are typically not 
shaggy like hairy leukoplakia, and they may occur anywhere in the oral cavity. They are often premalignant and 
should be evaluated by biopsy and histologic examination. See the image below. 
 
Ventral tongue in oral leukoplakia. 
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Lichen planus or lichenoid eruptions occur as autoimmune or allergic reactions to an unknown stimulus. In HIV-
infected patients, lichen planus often occurs on the buccal mucosa, typically with a reticulated pattern. Oral lichen 
planus may also be associated with cutaneous lesions. See the image below. 
 
Lateral tongue in lichen planus.  
 
{file63314}  
Lesions that clinically and histologically mimicked oral hairy leukoplakia but were not associated with EBV 
infection have been characterized as pseudo–hairy leukoplakia. 
Proliferative verrucous leukoplakia can have a papillary and roughened surface, which may simulate the corrugated 
surface of oral hairy leukoplakia. Proliferative verrucous leukoplakia is known for malignant transformation. The 
two examples on the tongue and gingiva in the images below showed squamous cell carcinoma with biopsy. 
 Proliferative verrucous leukoplakia of the lateral tongue; biopsy showed squamous cell carcinoma. 
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Proliferative verrucous leukoplakia of the gingiva; biopsy showed squamous cell carcinoma. 
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Differentials 
Candidiasis 
Condyloma Acuminatum 
Morsicatio buccarum, labiorum, and linguarum 
Cheek, lip, and tongue biting 
Oral Frictional Hyperkeratosis 
Oral Leukoplakia 
Proliferative Verrucous Leukoplakia 
White sponge nevus 
 
Workup 
Laboratory Studies 
In most cases of oral hairy leukoplakia (OHL), the diagnosis is established on clinical basis, while a 
definitive diagnosis requires both an appropriate histopathological appearance and the demonstration of 
Epstein-Barr virus (EBV) DNA, RNA, or protein within the epithelial cells of the lesion. 
Several immunohistochemical and in situ hybridization kits are commercially available for this 
purpose.{ref19} Tissue biopsy is indicated only if the lesions are unusual in appearance or ulcerated and 
suggest cancer. 
Procedures 
It is important to differentiate hairy leukoplakia from other, more serious, oral lesions that may have a 
similar clinical appearance. In some cases, biopsy and histologic examination are required to exclude 
cancer. 
Histologic Findings 
The histopathology of oral hairy leukoplakia (OHL) is characterized by the following five major features: 
 Hyperkeratosis of the upper epithelial layer that represents an altered pattern of keratin expression in 
the squamous epithelial cells: This hyperkeratosis is largely responsible for the characteristic shaggy 
or "hairy" gross appearance of the lesion. Superficial infections of the hyperkeratinized epithelium 
with bacteria or Candida may also be seen. 
 Parakeratosis of the superficial epithelial layer: This abnormal persistence of cell nuclei in the 
superficial epithelial layers may represent incomplete squamous differentiation. 
 Acanthosis of the stratum spinosum in the epithelial mid layer: This abnormal expansion of cells 
occurs with foci or layers of ballooning koilocyte-like cells. The nuclei have a homogenous ground-
glass appearance and may contain Cowdry type A intranuclear inclusions. 
 Minimal or no inflammation in the epithelial and subepithelial tissues 
 Histologically normal basal epithelial layer 
Although these characteristic histologic features of hairy leukoplakia are highly suggestive of the 
diagnosis, none is unique to the lesion. Thus, a definitive diagnosis of hairy leukoplakia requires both an 
appropriate histologic/cytologic appearance and demonstration of Epstein-Barr virus (EBV) DNA, RNA, or 
protein within the epithelial cells of the lesion. 
Treatment 
Medical Care 
As a benign lesion with low morbidity, oral hairy leukoplakia (OHL) does not require specific treatment in 
every case. Indications for treatment include symptoms attributable to the lesion, or a patient's desire to 
eliminate the lesion for cosmetic reasons. The variable natural history of the lesion and its tendency 
toward spontaneous resolution should be considered in any management decision. Several treatment 
options are available. 
Systemic antiviral therapy usually achieves resolution of the lesion within 1-2 weeks of therapy.{ref20} 
Oral therapy with acyclovir requires high doses (800 mg 5 times per day) to achieve therapeutic 
levels.{ref21} Valacyclovir (1000 mg 3 times a day) and famciclovir (500 mg 3 times a day) are newer 
antiviral drugs with higher oral bioavailability than acyclovir and can be dosed less often. Antiviral drugs 
inhibit productive Epstein-Barr virus (EBV) replication but do not eliminate the latent state of infection. 
Hairy leukoplakia often recurs several weeks after the cessation of antiviral therapy. 
Topical therapy with podophyllin resin 25% solution usually achieves resolution after 1-2 treatment 
applications. The treatments may temporarily cause local pain, discomfort, and alteration of taste. 
Podophyllin has cellular cytotoxic effects, but the mechanism of action in resolving hairy leukoplakia is not 
known. Again, hairy leukoplakia often recurs several weeks after successful podophyllin therapy.{ref22} 
Topical therapy with retinoic acid (tretinoin) has been reported to resolve hairy leukoplakia. Retinoic acids 
are known to inhibit EBV replication in vitro and induce epithelial cell differentiation. As with the antiviral 
agents and podophyllin, hairy leukoplakia often recurs several weeks after successful retinoic acid 
therapy. 
Ablative therapy can also be considered for small hairy leukoplakia lesions. Cryotherapy has been 
reported as successful but is not widely used.{ref23} 
Institution of HAART, considered to be the standard care in the United States, is useful in eliminating the 
lesions of oral hairy leukoplakia. 
Superinfection with Candida can be addressed with medical therapy. 
Consultations 
Consultations with dentists, dermatologists, or infectious disease specialists may be in order depending 
upon the underlying disease process resulting in oral hairy leukoplakia (OHL). 
Diet 
Diet may be as tolerated. 
Medication 
Medication Summary 
The goals of pharmacotherapy are to reduce morbidity and prevent complications. 
Medications 
Antiviral agents 
Nucleoside analogs initially are phosphorylated by viral thymidine kinase to eventually form a nucleoside 
triphosphate. 
Acyclovir (Zovirax) 
Acyclovir has affinity for viral thymidine kinase and, once phosphorylated, causes DNA chain termination when 
acted on by DNA polymerase. Patients experience less pain and faster resolution of lesions when used within 48 
hours from onset of an outbreak. Acyclovir may prevent recurrent outbreaks. Early initiation of therapy is 
imperative.  
Valacyclovir (Valtrex) 
Valacyclovir is a prodrug that is rapidly converted to the active drug acyclovir. It is more expensive but has a more 
convenient dosing regimen than acyclovir.  
Famciclovir (Famvir) 
Famciclovir is a prodrug that when biotransformed into the active metabolite, penciclovir, may inhibit viral DNA 
synthesis/replication. 
Ganciclovir (Cytovene, Vitrasert) 
Ganciclovir is indicated for CMV retinitis and the prevention of CMV infection in individuals who are HIV positive. 
Foscarnet (Foscavir) 
Foscarnet is indicated only for acyclovir-resistant mucocutaneous herpes simplex virus, which occurs almost 
exclusively in individuals who are HIV positive.  
Keratolytic agents 
These agents cause cornified epithelium to swell, soften, macerate, and then desquamate. 
Podophyllum resin (Pod-Ben-25, Podofin, Podocon-25) 
The major active constituent, podophyllotoxin, is a lipid-soluble compound that easily crosses cell membranes. 
Podophyllotoxin and its derivatives are potent cytotoxic agents that inhibit cell mitosis and deoxyribonucleic acid 
(DNA). Cell division is arrested, and other cellular processes are impaired, gradually resulting in the disruption of 
cells. 
Podophyllum resin arrests mitosis in the metaphase; the active agent is podophyllotoxin; the type of podophyllum 
resin used determines strength. American podophyllum contains one fourth the amount of Indian sources. It is used 
in symptomatic OHL.  
Antifungals 
These agents reduce Candida superinfection. 
Nystatin (Nilstat, Mycostatin, Nystex) 
Nystatin is a fungicidal and fungistatic antibiotic obtained from Streptomyces noursei; it is effective against various 
yeasts and yeastlike fungi. Nystatin changes the permeability of the fungal cell membrane after binding to cell 
membrane sterols, causing cellular contents to leak. Treatment should continue until 48 hours after the 
disappearance of symptoms. Nystatin is not absorbed significantly from the GI tract.  
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